RxDoctor Payments Data

Karla Moya-Crites

Family Medicine · Santa Fe, NMNPI 1649742966

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $991 and has fallen 82.9% since, to $169 in 2025. Among family medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,655in general payments, 2019–2025

Across 159 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$558
  • AbbVie$455
  • AstraZeneca$348
  • Lilly USA, LLC$235
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
  • Sanofi-aventis U.S. LLC$145
  • plus $735 from 17 others

What the payments were for

  • Food & beverage$2,63999%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,655 in reported general payments places this provider in the 90th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide38$37,066
OzempicSemaglutide23$35,304
JardianceEmpagliflozin36$31,510
FarxigaDapagliflozin Propanediol37$26,260
RybelsusSemaglutide13$19,259
MounjaroTirzepatide12$14,005
EliquisApixaban12$13,543
XareltoRivaroxaban13$8,454
LinzessLinaclotide11$5,736
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$3,782
Dexlansoprazole DrDexlansoprazole15$3,239
Albuterol Sulfate HfaAlbuterol Sulfate58$1,504
Omeprazole72$1,386
Venlafaxine Hcl ErVenlafaxine Hcl14$1,299
Atorvastatin Calcium116$1,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$54,56336 claims
Lilly USA, LLCTrulicity, Mounjaro$235$51,07050 claims
Boehringer IngelheimJardiance$131$31,51036 claims
AstraZenecaFarxiga$348$26,26037 claims
PfizerEliquis$142$13,54312 claims
Johnson & JohnsonXarelto$13$8,45413 claims
AbbVieLinzess$455$5,73611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →